Dilated Cardiomyopathy - Pipeline Review, H2 2018

Publisher Name :
Date: 10-Jul-2018
No. of pages: 65
Inquire Before Buying

Dilated Cardiomyopathy - Pipeline Review, H2 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Dilated Cardiomyopathy - Pipeline Review, H2 2018, provides an overview of the Dilated Cardiomyopathy (Cardiovascular) pipeline landscape.

Dilated cardiomyopathy (DCM) is a condition in which the heart's ability to pump blood is decreased because the heart's main pumping chamber, the left ventricle, is enlarged and weakened. Symptoms include Fatigue and weakness, Shortness of breath (dyspnea), lightheadedness, dizziness or fainting, persistent cough or wheezing, lack of appetite, sudden weight gain from fluid retention and swelling (edema) in legs, ankles and feet. Risk factors include family history, alcoholism, hypertension, cocaine abuse and metabolic disorders, such as thyroid disease or diabetes.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Dilated Cardiomyopathy - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Dilated Cardiomyopathy (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Dilated Cardiomyopathy (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Dilated Cardiomyopathy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase I, Preclinical and Discovery stages are 1, 4, 5 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Dilated Cardiomyopathy (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Dilated Cardiomyopathy (Cardiovascular).

- The pipeline guide reviews pipeline therapeutics for Dilated Cardiomyopathy (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Dilated Cardiomyopathy (Cardiovascular) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Dilated Cardiomyopathy (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Dilated Cardiomyopathy (Cardiovascular)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Dilated Cardiomyopathy (Cardiovascular).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Dilated Cardiomyopathy (Cardiovascular) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Dilated Cardiomyopathy - Pipeline Review, H2 2018

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Dilated Cardiomyopathy - Overview
Dilated Cardiomyopathy - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Dilated Cardiomyopathy - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Dilated Cardiomyopathy - Companies Involved in Therapeutics Development
Array BioPharma Inc
C&C BioPharma LLC
Capricor Therapeutics Inc
Celixir Ltd
Hemostemix Inc
Kasiak Research Pvt Ltd
MyoKardia Inc
Sanofi
Dilated Cardiomyopathy - Drug Profiles
ACP-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ARRY-797 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BC-007 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CAP-1002 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DCM-2 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Heartcel - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LUS-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Refacell-DCM - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SAR-440181 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit MEF2 for Cardiovascular Diseases - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stem Cell Therapy for Myocardial Infarction and Dilated Cardiomyopathy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
YS-1402 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Dilated Cardiomyopathy - Dormant Projects
Dilated Cardiomyopathy - Product Development Milestones
Featured News & Press Releases
Feb 26, 2018: Heart Failure Treatment from Berlin Cures Shows Promise in Phase 1 Study
Feb 14, 2018: MyoKardia Begins Patient Dosing in Phase 1b Clinical Study of MYK-491 in Dilated Cardiomyopathy Patients
Nov 02, 2017: MyoKardia Provides Update on MYK-491
Sep 27, 2017: MyoKardia Provides Update on MYK-491 Clinical Progress
Feb 02, 2017: First Subjects Dosed in MyoKardia Phase 1 Study of Dilated Cardiomyopathy Candidate MYK-491
Dec 02, 2016: MyoKardia Announces Receipt of Milestone Payment from Sanofi for DCM Candidate MYK-491
Aug 30, 2016: Array Presents Data from Cardiovascular Trial with ARRY-797 at the European Society of Cardiology Congress
Dec 17, 2013: Capricor Therapeutics Cleared to Begin Phase II Portion of ALLSTAR Clinical Trial with CAP-1002 in Patients Following Heart Attack
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Dilated Cardiomyopathy, H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products under Development by Universities/Institutes, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Universities/Institutes, H2 2018
Number of Products by Stage and Target, H2 2018
Number of Products by Stage and Mechanism of Action, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Dilated Cardiomyopathy - Pipeline by Array BioPharma Inc, H2 2018
Dilated Cardiomyopathy - Pipeline by C&C BioPharma LLC, H2 2018
Dilated Cardiomyopathy - Pipeline by Capricor Therapeutics Inc, H2 2018
Dilated Cardiomyopathy - Pipeline by Celixir Ltd, H2 2018
Dilated Cardiomyopathy - Pipeline by Hemostemix Inc, H2 2018
Dilated Cardiomyopathy - Pipeline by Kasiak Research Pvt Ltd, H2 2018
Dilated Cardiomyopathy - Pipeline by MyoKardia Inc, H2 2018
Dilated Cardiomyopathy - Pipeline by Sanofi, H2 2018
Dilated Cardiomyopathy - Dormant Projects, H2 2018

List of Figures
Number of Products under Development for Dilated Cardiomyopathy, H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products by Targets, H2 2018
Number of Products by Stage and Targets, H2 2018
Number of Products by Mechanism of Actions, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Molecule Types, H2 2018
Number of Products by Stage and Molecule Types, H2 2018
  • Hypotension - Pipeline Review, H2 2018
    Published: 10-Jul-2018        Price: US 2000 Onwards        Pages: 44
    Hypotension - Pipeline Review, H2 2018 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hypotension - Pipeline Review, H2 2018, provides an overview of the Hypotension (Cardiovascular) pipeline landscape. Low blood pressure, or hypotension, occurs when blood pressure during and after each heartbeat is much lower than usual. This means the heart, brain, and other parts of the body do not get enough blood. Symptoms i......
  • Thromboembolism - Pipeline Review, H2 2018
    Published: 10-Jul-2018        Price: US 2000 Onwards        Pages: 98
    Thromboembolism - Pipeline Review, H2 2018 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Thromboembolism - Pipeline Review, H2 2018, provides an overview of the Thromboembolism (Cardiovascular) pipeline landscape. When a blood clot (thrombus) breaks and travels in the blood, this is called a thromboembolism. Symptoms include warmth, edema, and erythema, and may also include dilated veins (collaterals) on the che......
  • Microscopic Polyangiitis (MPA) - Pipeline Review, H2 2018
    Published: 10-Jul-2018        Price: US 2000 Onwards        Pages: 43
    Microscopic Polyangiitis (MPA) - Pipeline Review, H2 2018 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Microscopic Polyangiitis (MPA) - Pipeline Review, H2 2018, provides an overview of the Microscopic Polyangiitis (MPA) (Cardiovascular) pipeline landscape. Microscopic polyangiitis (MPA) is an uncommon disease. It is the result of blood vessel inflammation which can damage organ systems. The area most commonly ......
  • Ischemia Reperfusion Injury - Pipeline Review, H2 2018
    Published: 10-Jul-2018        Price: US 2000 Onwards        Pages: 152
    Ischemia Reperfusion Injury - Pipeline Review, H2 2018 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Ischemia Reperfusion Injury - Pipeline Review, H2 2018, provides an overview of the Ischemia Reperfusion Injury (Cardiovascular) pipeline landscape. Ischemic reperfusion injury is the tissue damage that happens when blood supply returns to the tissue after a period of lack of oxygen. The absence of oxygen and nut......
  • Left Ventricular Dysfunction - Pipeline Review, H2 2018
    Published: 10-Jul-2018        Price: US 2000 Onwards        Pages: 48
    Left Ventricular Dysfunction - Pipeline Review, H2 2018 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Left Ventricular Dysfunction - Pipeline Review, H2 2018, provides an overview of the Left Ventricular Dysfunction (Cardiovascular) pipeline landscape. Left ventricular dysfunction is the most common cause of congestive heart failure. Symptoms include fluid retention, dizziness, fatigue, weakness, irregular heart......
  • Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline Review, H2 2018
    Published: 10-Jul-2018        Price: US 2000 Onwards        Pages: 193
    Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline Review, H2 2018 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline Review, H2 2018, provides an overview of the Coronary Artery Disease (CAD) (Ischemic Heart Disease) (Cardiovascular) pipeline landscape. Coronary artery disease (CAD) is the most common type of heart disease. CAD happens ......
  • Global Atorvastatin Calcium Market by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 09-Jul-2018        Price: US 3480 Onwards        Pages: 146
    Atorvastatin calcium is a pharmaceutical raw material in the production of atorvastatin calcium drug (trade name: Lipitor), which is a prescription medicine that lowers the LDL cholesterol and triglycerides in the blood and can raise HDL cholesterol as well. Atorvastatin calcium usually is white powder and whose CAS number is 134523-03-8. Scope of the Report: This report focuses on the Atorvastatin Calcium in global market, especially in North America, Europe and Asia-Pacif......
  • Global (North America, Europe, Asia-Pacific, South America, Middle East and Africa) Atorvastatin Calcium Market 2018, Forecast to 2023
    Published: 09-Jul-2018        Price: US 4880 Onwards        Pages: 154
    Atorvastatin calcium is a pharmaceutical raw material in the production of atorvastatin calcium drug (trade name: Lipitor), which is a prescription medicine that lowers the LDL cholesterol and triglycerides in the blood and can raise HDL cholesterol as well. Atorvastatin calcium usually is white powder and whose CAS number is 134523-03-8. Scope of the Report: This report focuses on the Atorvastatin Calcium in global market, especially in North America, Europe and Asia-Pacif......
  • Global Rosuvastatin Calcium Market by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 09-Jul-2018        Price: US 3480 Onwards        Pages: 146
    Rosuvastatin calcium (CAS 147098-20-2, molecular formula being C44H54CaF2N6O12S2) is the active pharmaceutical ingredient for the once-a-day dyslipidaemia treatment Crestor, it is one approved API which can be used to reduce the risk of heart attack and stroke.Rosuvastatin calcium is a hygroscopic powder suitable for the manufacture of tablets and capsules. The appropriate excipients need to be added. The particle size of the product is designed in such a way that optimal dissolution can be obta......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs